Analysts Anticipate Flexion Therapeutics Inc (NASDAQ:FLXN) to Post -$1.06 Earnings Per Share

Analysts expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will post earnings of ($1.06) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Flexion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.08) and the highest estimate coming in at ($1.04). Flexion Therapeutics reported earnings of ($1.16) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 8.6%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($4.07) per share for the current financial year, with EPS estimates ranging from ($4.18) to ($3.93). For the next fiscal year, analysts expect that the company will post earnings of ($2.44) per share, with EPS estimates ranging from ($2.95) to ($1.68). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative net margin of 549.07% and a negative return on equity of 131.94%. The company had revenue of $10.56 million for the quarter, compared to analysts’ expectations of $11.10 million.

A number of research analysts recently issued reports on the stock. Northland Securities reissued a “buy” rating and issued a $20.00 price objective on shares of Flexion Therapeutics in a research note on Friday, March 1st. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 20th. BidaskClub cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 7th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. Finally, Raymond James reissued a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, March 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Flexion Therapeutics has a consensus rating of “Buy” and an average target price of $23.71.

In related news, CFO David Arkowitz bought 2,500 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were purchased at an average price of $11.05 per share, with a total value of $27,625.00. Following the completion of the purchase, the chief financial officer now owns 89,424 shares in the company, valued at approximately $988,135.20. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director C Ann Merrifield bought 8,000 shares of the firm’s stock in a transaction on Thursday, May 23rd. The shares were bought at an average cost of $12.64 per share, for a total transaction of $101,120.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $126,400. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 18,512 shares of company stock worth $226,775. Insiders own 16.01% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of FLXN. State Board of Administration of Florida Retirement System lifted its stake in shares of Flexion Therapeutics by 4.9% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 16,668 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 772 shares in the last quarter. Macquarie Group Ltd. lifted its stake in Flexion Therapeutics by 1.3% in the 1st quarter. Macquarie Group Ltd. now owns 69,379 shares of the specialty pharmaceutical company’s stock worth $866,000 after purchasing an additional 895 shares in the last quarter. Swiss National Bank lifted its stake in Flexion Therapeutics by 3.2% in the 1st quarter. Swiss National Bank now owns 55,211 shares of the specialty pharmaceutical company’s stock worth $689,000 after purchasing an additional 1,700 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Flexion Therapeutics by 8.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 23,075 shares of the specialty pharmaceutical company’s stock worth $288,000 after purchasing an additional 1,876 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in Flexion Therapeutics by 22.4% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,300 shares of the specialty pharmaceutical company’s stock worth $343,000 after purchasing an additional 2,800 shares in the last quarter. 89.88% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:FLXN opened at $11.28 on Tuesday. The company has a market capitalization of $418.30 million, a P/E ratio of -2.51 and a beta of 1.40. The company has a current ratio of 6.32, a quick ratio of 6.06 and a debt-to-equity ratio of 2.10. Flexion Therapeutics has a 1 year low of $9.65 and a 1 year high of $29.10.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Read More: Hedge Funds

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.